September 1 2021 | Philadelphia, PA

Mufson Howe Hunter & Company (“MHH”) is pleased to announce that PDS Life Sciences (“PDS” or the “Company”), a leading provider of software and outsourced services to the global life sciences market, has been acquired by Instem plc (“Instem”).

Headquartered in Switzerland, with offices in the United States and Japan, PDS has been a direct competitor of Instem, providing software and outsourced services for non-clinical study management and regulatory submissions using SEND (the Standard for the Exchange of Non-clinical Data). Seven of the world’s top ten pharmaceutical companies rely on PDS, as do leading Contract Research Organizations, chemical companies, universities, and regulatory agencies.

“This was a natural next step in our quest to help clients do more and go further than ever before. MHH provided us with excellent advice throughout the process and was instrumental in helping us achieve an outstanding outcome for all stakeholders,” said Vicente Nogués, CEO at PDS.

MHH acted as PDS’s exclusive financial advisor for the transaction. This engagement underscores MHH’s commitment to partnering with leading vertical software and technology-enabled service companies and highlights the firm’s deep domain expertise and established relationships in the sector.